Financial Report: Teva Pharmaceutical Industries 2Q

Teva 2Q

2Q Revenue: $3.4 billion (+20%)

2Q Earnings: $521 million (-2%)

Comments: Pharmaceutical sales in the quarter in North America were $2.1 billion (+36%). Sales in Europe were down 4% to $732 million. International sales were $481 million (+20%). Sales of Copaxone were up 21% in the quarter to $682 million. Sales of Azilect were $55 million (+31%). Sales in the women’s-health business, acquired from Barr, were $80 million (+4%). The increase reflected higher sales of the Plan B contraceptive. Sales of respiratory products were up 13% to $189 million. R&D expenses in the quarter were $169 million, or 5% of sales, compared to $198 million in 2Q08.

Sign up today for Contracting & Outsourcing 2009!
dhruv_cp.rodpub.com/2009conference